<DOC>
	<DOCNO>NCT01156545</DOCNO>
	<brief_summary>The investigator hypothesize simvastatin may enhance sensitivity BIBW 2992 non-adenocarcinoma relatively resistant TKIs . Based data , investigator research effectiveness compare BIBW2992 , irreversible EGFR-TKI , plus simvastatin BIBW2992 alone set randomize phase II study previously treat patient advanced non-adenocarcinomatous non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>BIBW 2992 Plus Simvastatin vs. BIBW 2992 Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC</brief_title>
	<detailed_description>One main reason resistance EGFR tyrosine kinase inhibitor ( TKIs ) alternative mechanisms persistent activate EGFR downstream signaling , include RAS/Erk PI3K/Akt kinase pathways . Therefore , simultaneous inhibition pathway would necessary reduce tumor cell survival effectively . One candidate combination concurrent use EGFR-TKIs statin , irreversible inhibitor 3-hydroxy-3-methylglutaryl-coenzyme A ( HMG-CoA ) reductase use treat hypercholesterolemia block mevalonate biosynthesis pathway . Beside cholesterol lower effect , statins show induce apoptosis several tumor type . It affect synthesis product mevalonate pathway isoprenoids , use substrate prenylation . Attachment isoprenoids RAS proteins facilitates anchor cell membrane carry role . By interrupt biosynthesis mevalonate , statins inhibit activation RAS downstream signal cascade , include RAF/MEK/ERK PI3K/AKT , play critical role regulation cell survival proliferation . Therefore , seem promising therapeutic approach overcome tumor resistance EGFR-TKIs , associate RAS activation . According recent clinical result phase II trial , randomize phase II study gefitinib without simvastatin previously treat patient advanced NSCLC conduct Han et al.37 gefitinib plus simvastatin combination produce high response rate gefitinib alone patient non-adenocarcinoma ( 5/13 [ 39 % ] v 1/13 [ 8 % ] , P=0.06 ) . This finding suggest simvastatin may enhance sensitivity gefitinib non-adenocarcinoma relatively resistant gefitinib . Moreover , Mantha et al.35 demonstrated combination gefitinib lovastatin show significant synergic cytotoxic effect vitro total 16 squamous cell carcinoma , NSCLC , colon carcinoma cell line . Of special interest , cell line posse activate mutation EGFR , confer increase sensitivity gefitinib . Nevertheless , combine lovastatin gefitinib induce significant inhibition AKT activation either agent alone . Additionally , lovastatin significantly enhance sensitivity gefitinib treatment regardless PTEN loss glioblastoma cell line . These result suggest statins augment EGFR inhibition .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1 . Pathologically confirm diagnosis Stage IIIB Stage IV nonadenocarcinomatous nonsmall cell lung cancer ( e.g. , squamous cell large cell carcinoma ) . ( The 7th edition TNM classification lung cancer47See Appendix 6 ) 2 . Progressive disease follow first second line cytotoxic chemotherapy regimen ( ) include least one platinumcontaining regimen . 3 . Measurable disease accord RECIST 1.1.40 4 . Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 2.41 5 . Age ≥ 18 year . 6 . Life expectancy least three ( 3 ) month . 7 . Written inform consent consistent ICHGCP guideline . 1 . More three ( 3 ) prior cytotoxic chemotherapy treatment regimen relapse metastatic NSCLC . 2 . Prior treatment EGFR target small molecule antibody ( e.g. , gefitinib , erlotinib , cetuximab ) . 3 . Chemotherapy , hormonal therapy ( megestrol acetate steroid require maintenance noncancer therapy ) , immunotherapy surgery ( biopsy ) within 4 week prior study entry . 4 . Radiotherapy within 2 week prior study entry . Only palliative radiotherapy nontarget lesion allow entered case . 5 . Active brain metastasis clinically significant neurological symptom sign . Patients brain metastasis allow unless clinically significant neurological symptom sign . 6 . Any current malignancy malignancy diagnose within past five ( 5 ) year ( nonmelanomatous skin cancer situ cervical cancer ) . 7 . Known preexist interstitial lung disease . 8 . Significant recent acute gastrointestinal disorder diarrhea major symptom e.g . Crohn 's disease , malabsorption CTC grade ≥2 diarrhea etiology . 9 . Absolute neutrophil count ( ANC ) &lt; 1500 / mm3 . 10 . Platelet count &lt; 100,000 / mm3 . 11 . Serum creatinine &gt; 1.5 time upper limit normal ( ULN ) creatinine clearance &lt; 60 ml / min 12 . Bilirubin &gt; 1.5 time upper limit normal . 13 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &gt; 3 time upper limit normal ( ULN ) ( relate liver metastases &gt; 5 time ULN ) . 14 . History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure NYHA classification 3 , unstable angina poorly control arrhythmia . Myocardial infarction within 6 month prior study entrance . 15 . Cardiac leave ventricular function rest ejection fraction le 50 % . 16 . Any concomitant serious illness organ system dysfunction opinion investigator would either compromise patient safety interfere evaluation safety test drug . 17 . Women childbearing potential , men able father child , unwilling use medically acceptable method contraception trial . 18 . Pregnancy breastfeed . 19 . Patients unable comply protocol . 20 . Active hepatitis B infection , active hepatitis C infection know HIV carrier . 21 . Known suspected active drug alcohol abuse . 22 . Requirement treatment prohibit concomitant medication list Section 4.2.2 . 23 . Any contraindication therapy simvastatin . 24 . Known hypersensitivity BIBW 2992 excipients trial drug . 25 . Use investigational drug within 4 week randomization ( unless long time period require local regulation ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>BIBW 2992</keyword>
	<keyword>Simvastatin</keyword>
	<keyword>NSCLC</keyword>
	<keyword>advanced stage</keyword>
	<keyword>previously treat patient</keyword>
	<keyword>non-adenocarcinoma</keyword>
</DOC>